Epcoritamab

Epcoritamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/MS4A1/CD20, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B cell malignancies.

Target	CD3E/MS4A1/CD20
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG4 Kappa-Lambda
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on CD3E/MS4A1/CD20

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue